PBH Prestige Consumer Healthcare Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1295947 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY-22.8%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR1.2%
Net income 3-yr CAGR—
Margins
Gross margin52.5%
Operating margin25.0%
Net margin13.3%
FCF margin18.4%
EBITDA margin28.1%
Returns
ROE8.2%
ROA3.8%
ROIC (approx.)6.9%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets58.8%
Debt / equity1.07x
Current ratio2.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.09B | $1.14B |
| Cost of revenue | $493.13M | $503.30M |
| Gross profit | $595.58M | $634.46M |
| SG&A expense | $116.45M | $108.21M |
| Operating income | $309.41M | $336.77M |
| Interest expense | — | $1.80M |
| Pretax income | $257.50M | $284.19M |
| Income tax | $67.19M | $69.58M |
| Net income | $190.30M | $214.60M |
| EBITDA | $340.68M | $366.95M |
| EPS (basic) | 3.93 | 4.32 |
| EPS (diluted) | 3.91 | 4.29 |
| Weighted avg. shares (diluted) | 48.72M | 50.08M |
| Banking | ||
| Net interest income | -$42.34M | -$47.63M |
| Provision for credit losses | $10.33M | $0 |
| Balance sheet | ||
| Cash & equivalents | $63.87M | $97.88M |
| Receivables | $191.92M | $194.29M |
| Inventory | $159.13M | $147.71M |
| Current assets | $431.48M | $448.33M |
| PP&E, net | $121.69M | $74.55M |
| Goodwill | $581.11M | $527.42M |
| Intangibles | $2.30B | $2.30B |
| Total assets | $3.49B | $3.40B |
| Current liabilities | $120.92M | $106.62M |
| Short-term debt | $0 | — |
| Long-term debt | $993.95M | $992.36M |
| Total debt | $993.95M | $992.36M |
| Total liabilities | $1.61B | $1.57B |
| Shareholders' equity | $1.89B | $1.83B |
| Net debt | $930.09M | $894.47M |
| Cash flow statement | ||
| Operating cash flow | $257.63M | $251.51M |
| Capital expenditure | $11.18M | $8.22M |
| Free cash flow | $246.45M | $243.29M |
| Investing cash flow | -$136.84M | -$17.45M |
| Financing cash flow | -$156.06M | -$182.07M |
| Depreciation & amortization | $31.27M | $30.17M |
| Stock-based compensation | $10.84M | $11.16M |
| Share buybacks | $156.28M | $51.51M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.